Shanz - Pedia Ii 2.05
Shanz - Pedia Ii 2.05
Shanz - Pedia Ii 2.05
05
TB DIAGNOSIS IN CHILDREN
CLASS I : TB EXPOSURE CLASS II: TB INFECTION CLASS III: TB DISEASE CLASS IV: TB INACTIVE
• (-) Tuberculin test • (+) Exposure • (+) exposure • With/without exposure
• No S/S • (+) Tuberculin test • (+) Mantoux/tuberculin test • With/without previous treatment
• (-) CXR • No S/S • S/S • CXR: healed or calcified TB
• (-) CXR • (+) CXR • (+) Mantoux test
• Caseation necrosis • No S/S
• (-) Smear or culture
DOH PROGRAM
EARLY DX & CURE OF SMEAR (+) ADULTS = DECREASE TB INFECTION AMONG CHILDREN
BCG IMMUNIZATION IN INFANTS = DECREASE EXTRAPULMONARY TB
BCG PPD
• Produce innocuous primary infection due to bacillus of Calmette and • Screening tool
Guerin • Negative: may be in state of anergy
• Prevents dissemination of disease • False negative: malnourished (negative nitrogen balance), fever,
• Doesn’t prevent infection of MTB dehydration
• 0.05 mL for newborn & neonate
• 0.1mL for infants
• Intradermal R deltoid / buttock
• Multiple doses NOT recommended
TB TREATMENT IN CHILDREN
AntiTB side effects ISONIAZID PREVENTIVE THERAPY LATENT TB INFECTION TREATMENT RESPONSE DOTS
EVALUATION
• Ethambutol: optic neuritis (>15- • Children < 5 yo • HIGH BURDEN: low to middle • CXR infiltrate clear in 2-9 mo • Microscopes: confirmation
20 mg) • Asymptomatic people living with HIV income (6 mo of INH) • Hilar adenopathy disappear 2-3 yr • Medicine: anti TB drug
• Isoniazid (pyridoxine def) • Isoniazid 10 mg/kg/day x 6 mo (max • INH + RFT weekly x 3 mo • Complete resorption 6-12 weeks • Observer: community health workers
• Streptomycin (ototoxic, CN 8 300 mg/day) • Low incidence: 6 H vs 9H: see swallowing
dysfunction) Resource requirements • Reporting books: documentation until
• Rifampicin (orange urine) Feasibility cure
Acceptability by patients • Funding: political support